147 related articles for article (PubMed ID: 26371746)
1. Bendamustine reactivates latent Epstein-Barr virus.
Fernandez SG; Miranda JJ
Leuk Lymphoma; 2016 May; 57(5):1208-10. PubMed ID: 26371746
[No Abstract] [Full Text] [Related]
2. Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?
Gordon MJ; Lewis LD; Brown JR; Danilov AV
Expert Rev Hematol; 2017 Aug; 10(8):707-718. PubMed ID: 28664772
[TBL] [Abstract][Full Text] [Related]
3. Bendamustine: role and evidence in lymphoma therapy, an overview.
Derenzini E; Zinzani PL; Cheson BD
Leuk Lymphoma; 2014 Jul; 55(7):1471-8. PubMed ID: 24180334
[TBL] [Abstract][Full Text] [Related]
4. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
Prediletto I; Farag SA; Bacher U; Jeker B; Mansouri Taleghani B; Brégy R; Zander T; Betticher D; Egger T; Novak U; Pabst T
Bone Marrow Transplant; 2019 Dec; 54(12):1923-1925. PubMed ID: 30890768
[No Abstract] [Full Text] [Related]
5. Chaetocin reactivates the lytic replication of Epstein-Barr virus from latency via reactive oxygen species.
Zhang S; Yin J; Zhong J
Sci China Life Sci; 2017 Jan; 60(1):66-71. PubMed ID: 28063010
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of action and clinical effectiveness of the newly approved anti-cancer drug bendamustine].
Furukawa Y; Hiraoka N; Wada T; Kikuchi J; Kano Y
Nihon Yakurigaku Zasshi; 2011 Jul; 138(1):26-32. PubMed ID: 21747206
[No Abstract] [Full Text] [Related]
7. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
8. [Two cases of malignant lymphoma with reactivation of resolved hepatitis B virus infection after bendamustine hydrochloride monotherapy].
Hiraki Y; Kawano A; Shigematsu H; Miki K; Nomura H; Shimoda S
Nihon Shokakibyo Gakkai Zasshi; 2016 Sep; 113(9):1582-7. PubMed ID: 27593368
[TBL] [Abstract][Full Text] [Related]
9. Conjunctival lymphoma.
Li JJ; Chen W; Sadeghi N
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31296640
[No Abstract] [Full Text] [Related]
10. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
Howell M; Gibb A; Radford J; Linton K
Br J Haematol; 2017 Dec; 179(5):841-843. PubMed ID: 27447404
[No Abstract] [Full Text] [Related]
11. Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.
Martínez-Calle N; Hartley S; Ahearne M; Kasenda B; Beech A; Knight H; Balotis C; Kennedy B; Wagner S; Dyer MJS; Smith D; McMillan AK; Miall F; Bishton M; Fox CP
Br J Haematol; 2019 Mar; 184(6):957-968. PubMed ID: 30548597
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
14. Treating the Hodgkin's Lymphoma Variant of Richter's Transformation.
Zahid MF
J Coll Physicians Surg Pak; 2016 Apr; 26(4):344-5. PubMed ID: 27097715
[No Abstract] [Full Text] [Related]
15. Inhibitory effects of lantadenes and related triterpenoids on Epstein-Barr virus activation.
Inada A; Nakanishi T; Tokuda H; Nishino H; Iwashima A; Sharma OP
Planta Med; 1995 Dec; 61(6):558-9. PubMed ID: 8824951
[TBL] [Abstract][Full Text] [Related]
16. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update.
Cheson BD; Brugger W; Damaj G; Dreyling M; Kahl B; Kimby E; Ogura M; Weidmann E; Wendtner CM; Zinzani PL
Leuk Lymphoma; 2016; 57(4):766-82. PubMed ID: 26592922
[TBL] [Abstract][Full Text] [Related]
17. Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.
Stewart JP; McGown AT; Prendiville J; Pettit GR; Fox BW; Arrand JR
Cancer Chemother Pharmacol; 1993; 33(1):89-91. PubMed ID: 8269596
[TBL] [Abstract][Full Text] [Related]
18. [Latent infection and reactivation of Epstein-Barr virus].
Daikoku T
Nihon Rinsho; 2006 Mar; 64 Suppl 3():584-8. PubMed ID: 16615539
[No Abstract] [Full Text] [Related]
19. Correlation between reduction potentials and inhibitory effects on Epstein-Barr virus activation of poly-substituted anthraquinones.
Koyama J; Morita I; Kobayashi N; Osakai T; Nishino H; Tokuda H
Cancer Lett; 2005 Jul; 225(2):193-8. PubMed ID: 15978323
[TBL] [Abstract][Full Text] [Related]
20. The role of bendamustine in the management of plasma cell myeloma.
Gertz MA
Leuk Lymphoma; 2015 May; 56(5):1195-6. PubMed ID: 25347428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
